Navigation Links
Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
Date:3/11/2008

BRISBANE, Australia, March 11 /PRNewswire-FirstCall/ -- Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today announced the commencement of its global phase 3 study investigating PI-88 as an adjuvant treatment for primary liver cancer (hepatocellular carcinoma, HCC) following curative resection with the first patient having been randomized onto the study. The study is known globally as PATHWAY (PI-88 in the adjuvant treatment of HCC). The first patient to enter the trial is from Singapore.

Dr. Ronnie Poon, Ph.D., M.D., global lead investigator for PATHWAY, commented, "My colleagues and I are encouraged by the phase 2 data that Progen has generated for PI-88 in this challenging disease, for which there are no approved treatment options. If PATHWAY is successful, PI-88 could change the standard of care for resected liver cancer patients."

PATHWAY, a double-blinded, placebo-controlled study, has been designed to establish the efficacy and safety of PI-88 in the post resection liver cancer setting. The trial will recruit approximately 600 patients at about 65-70 hospitals in more than a dozen countries. Disease-free survival, a measure of the average length of time that patients remain free of tumor recurrence, is the primary endpoint. Upon completion of this trial, the results are expected to form the basis of global registration filings for PI-88.

Justus Homburg, Progen's CEO, said, "Commencement of this trial represents a significant milestone for Progen. We have designed this trial in collaboration with world experts in this field of medicine, and with USA FDA Fast Track and EU EMEA Orphan Drug Status, its initiation underscores our commitment to making this important drug rapidly available to patients who currently have few treatment options available."

Liver cancer is one of the top five causes of cancer deaths in the world, with over half a million new cases per year. Although surgical resection is one of the few treatment options with curative potential, recurrence is common within the first 12 to 15 months following surgery and five-year survival following resection is less than 50%.

Dr. James Garner, Progen's Vice President of Clinical and Medical Affairs, added, "Since the release of our promising phase 2 data last year, our team has worked tirelessly to design a world-class phase 3 trial for PI-88 in liver cancer. We are very thankful for the support of key opinion leaders and clinicians all over the world, many of whom will now be serving as investigators in PATHWAY. While the study is starting later than we had hoped as a result of some delays opening sites due to a greater-than-expected impact from holidays over the past couple of months, Progen continues to aggressively drive country regulatory and hospital ethics approvals to conduct this phase 3 trial."

The study now has regulatory approval in almost half of the participating countries and more than a dozen sites have been granted approval by ethics committees. Sites are being initiated so as to be able to commence patient recruitment as soon as these necessary approvals have been granted.

About PI-88: PI-88 is one of a new class of multi-targeted cytostatic cancer therapeutics. It is a novel anti-cancer compound with a first-in-class mechanism as a heparan sulfate mimetic. Its anti-tumor activity is based on inhibition of two biological processes -- angiogenesis (the growth of new blood vessels) and metastasis (the spread of cancer to other sites) -- critical to the growth and progression of cancer. In April 2007, data from a randomised phase 2 trial in the post resection liver cancer setting was presented at the European Association for the Study of the Liver (EASL) meeting in Barcelona, Spain. PI-88, in this disease setting, has been granted Orphan Drug designation by the European Medicines Evaluation Agency (EMEA) and Fast Track designation by the United States Food and Drug Administration (FDA). These results provide Progen with confidence in the potential of PI-88 for this indication and we are therefore aggressively pursuing its development towards registration and commercialization.

About the phase 3 study: The phase 3 study investigating PI-88 as a post- resection treatment for hepatocellular carcinoma (HCC, primary liver cancer) following curative resection is a double-blinded, placebo-controlled study that has been designed to establish the efficacy and safety of PI-88 in the post-resection HCC setting. The trial will recruit approximately 600 patients at 65-70 hospitals in more than a dozen countries. Disease-free survival is the study's primary endpoint. Upon completion of this trial, the results are expected to form the basis of global regulatory filings for PI-88.

About Progen: Progen Pharmaceuticals is a globally focused biotechnology company committed to the discovery, development and commercialization of small molecule pharmaceuticals primarily for the treatment of cancer. Progen has operations in Australia and the US.

Progen Information: Media and Investor Relations

Linton Burns Australia:

Progen Pharmaceuticals Limited Cindy Ingram

T: +61 7 3842 3333 Progen Pharmaceuticals Limited

E: lintonb@progen-pharma.com T: +61 7 3842 3333

E: cindyi@progen-pharma.com

Media Relations USA: Investor Relations USA:

Robert D. Stanislaro Evan Smith

Financial Dynamics Financial Dynamics

T: 212-850-5657 T: 212-850-5606

E: robert.stanislaro@fd.com E: evan.smith@fd.com

This press release contains forward-looking statements that are based on current management expectations. These statements may differ materially from actual future events or results due to certain risks and uncertainties, including without limitation, risks associated with drug development and manufacture, risks inherent in the extensive regulatory approval process mandated by the United States Food and Drug Administration and the Australian Therapeutic Goods Administration, delays in obtaining the necessary approvals for clinical testing, patient recruitment, delays in the conduct of clinical trials, market acceptance of PI-88, PI-166 and other drugs, future capital needs, general economic conditions, and other risks and uncertainties detailed from time to time in the Company's filings with the Australian Securities Exchange and the United States Securities and Exchange Commission. Moreover, there can be no assurance that others will not independently develop similar products or processes or design around patents owned or licensed by the Company, or that patents owned or licensed by the Company will provide meaningful protection or competitive advantages.


'/>"/>
SOURCE Progen Pharmaceuticals Limited
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Progen Provides Update on Phase 3 Clinical Program for PI-88 in Liver Cancer
2. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
3. Progen Announces PI-88 Phase 2 Lung Cancer Results
4. Progen Pharmaceuticals Announces Fiscal 2007 Financial Results
5. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
6. Inclinix Announces New Patent for Expert System Platform
7. Genzyme Announces Presentation of New Positive Data on Carticel(R)
8. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
9. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
10. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
11. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... 18, 2017 Cogentix Medical, Inc. (NASDAQ: CGNT), ... Urology, Uro/Gyn and Gynecology markets with innovative and proprietary ... ended March 31, 2017 after the market close on ... will host a conference call and webcast to discuss ... 2, 2017 at 4:30 p.m. Eastern Time (3:30 p.m. ...
(Date:4/18/2017)... DUBLIN , April 18, 2017 Research ... Devices Market 2017-2021" report to their offering. ... The global arthroscopy devices market to grow at ... The report, Global Arthroscopy Devices Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
(Date:4/18/2017)... SAN DIEGO and BLOOMINGTON, ... Pharmaceuticals, Inc. (NASDAQ: IMMY ) ("Imprimis"), ... d/b/a Precision Lens ("Precision Lens"), today announced the ... Under the agreement, Precision Lens will deploy a ... into select geographies in the U.S., primarily focused ...
Breaking Medicine Technology:
(Date:4/21/2017)... MA (PRWEB) , ... April 21, 2017 , ... ... University professor Christopher Salas-Wright finds that youth violence is declining—and at noteworthy rates. ... the relative proportion of young people involved in violence in the United States. ...
(Date:4/21/2017)... ... April 21, 2017 , ... Young Asset Protection, ... to communities throughout the greater Pittsburgh metropolitan region, is joining forces with the ... bicycles for differently-abled children. , Variety the Children’s Charity is a national organization ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... ... announced it’s been named Agency of Record (AOR) for Theravent, Inc. , ... eliminate snoring. Theravent’s parent company, Foundation Consumer Healthcare, is now working to expand ...
(Date:4/21/2017)... British Columbia (PRWEB) , ... April 21, 2017 , ... ... at treating people who wish to overcome their mental health struggles. The Alive team ... Director Vic LeBouthillier says: “Our approach in dealing with a mental health struggle is ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... seeking candidates to serve on its Accreditation and Standards Committees to support ... mission is improving image quality and reducing patient radiation dose,” reports Eliot ...
Breaking Medicine News(10 mins):